Equity Financing ImpactThe 12-month price target is lowered to $4.00 from $8.00 due to dilution from the recent capital raise.
Future Financing ConcernsMore dilution may be required for future financing considering the current share price trading near a 52-week low and overall market dynamics.
Risks And ChallengesRisks include failure of NPM-115 in clinical trials, failure to secure regulatory approval, and failure to achieve commercial success due to market size, penetration rate, and competition.